Healthcare solutions company Owens & Minor Inc (NYSE:OMI) on Tuesday introduced ByramConnect, a digital health platform designed to support Byram Healthcare customers managing diabetes and other chronic conditions.
Powered by the Welldoc App, the platform offers AI-driven health coaching, self-tracking and personalised insights to improve patient outcomes.
ByramConnect is an FDA-cleared class II software as a medical device intended for patients with type 1 or type 2 diabetes. Clinical studies show that users experienced improvements in A1C levels, blood pressure and weight management. The app integrates data from fitness trackers, glucose monitors, blood pressure monitors and other connected health devices.
Key features include AI-driven digital coaching, diet and nutrition support, GLP-1 medication tracking and mental well-being guidance. Patients receive personalised health reports with actionable insights to share with their healthcare providers.
The platform is available at no additional cost exclusively to Byram Healthcare diabetes customers. Eligible users will receive email invitations with an access code to download the app on iOS and Android devices.
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117